儿童维拉佐酮摄入的剂量与结局评估
该研究基于美国国家毒物数据系统2011—2016年数据,回顾性分析753例<6岁儿童单一维拉佐酮暴露。49.0%(n=369)出现至少一种临床效应,剂量增加与医疗设施收治(p<.001)及严重结局(p<.001)比例升高相关。≤2岁儿童收治率(33.8% vs 23.1%)和严重结局比例(27.0% vs 17.7%)均高于3—5岁儿童。作者认为维拉佐酮对<6岁儿童构成独特且可能严重的威胁,暴露后应尽快临床评估,并反对在进一步研究前对该人群超说明书使用。
要点
- 753例<6岁儿童维拉佐酮单一暴露中,49.0%(n=369)出现至少一种临床效应。
- 摄入剂量越高,医疗设施收治比例(p<.001)和严重结局比例(p<.001)均升高。
- ≤2岁儿童收治率33.8% vs 3—5岁23.1%,严重结局27.0% vs 17.7%。
- 摄入剂量低至10 mg的儿童中观察到昏迷、癫痫、共济失调、幻觉/妄想等临床效应。
- 作者认为<6岁儿童维拉佐酮暴露应尽快在临床环境中评估,并反对该人群超说明书使用。
适用人群与场景
- 美国毒物控制中心报告的<6岁儿童单一维拉佐酮暴露,数据来自2011—2016年美国国家毒物数据系统。
红旗征与不能漏的情况
- 摄入剂量低至10 mg的儿童中观察到昏迷、癫痫、共济失调、幻觉/妄想等临床效应。
- ≤2岁儿童较3—5岁儿童有更高比例的医疗设施收治(33.8% vs 23.1%)和严重结局(27.0% vs 17.7%)。
研究设计与关键结果
- 回顾性分析美国国家毒物数据系统2011—2016年数据,纳入753例<6岁儿童单一维拉佐酮暴露。
- 49.0%(n=369)出现至少一种临床效应;596例(79%)报告了摄入剂量。
- 出现主要效应的中位剂量为50.0 mg(均值106.0),中度为40.0 mg(均值81.1)。
- 出现主要效应的儿童中50.0%、中度效应中54.0%摄入剂量≤40 mg。
- 摄入剂量增加时,医疗设施收治比例(p<.001)和严重结局比例(p<.001)均升高。
- ≤2岁儿童医疗设施收治率33.8% vs 3—5岁23.1%,严重结局27.0% vs 17.7%。
- 摄入剂量低至10 mg的儿童中观察到昏迷、癫痫、共济失调、幻觉/妄想等临床效应。
证据类型、等级与局限
- 证据类型:基于美国国家毒物数据系统的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为<6岁儿童维拉佐酮暴露应尽快在临床环境中评估。
- 作者认为在进一步研究该人群安全性之前,应反对对<6岁儿童超说明书使用维拉佐酮。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Selective serotonin reuptake inhibitor (SSRI) exposures among children younger than 6 years of age are generally well tolerated. Vilazodone is an SSRI with partial agonism at the 5-HT1A receptor with demonstrated clinical efficacy for depression whose off-label usage is likely to increase. Recent evidence suggests that unintentional ingestion of vilazodone in children under 6 years old is associated with more severe clinical effects than other SSRIs. We chose to evaluate dose and outcomes for pediatric vilazodone ingestions.
METHODS: A retrospective analysis of single-substance exposures associated with vilazodone among children younger than 6 years of age from 2011 through 2016 was conducted using data from the National Poison Data System.
RESULTS: During 2011-2016, 753 vilazodone ingestions among children <6 years old were reported to US poison control centers. A near majority (49.0%, n = 369) experienced one or more clinical effects. The dose ingested was reported for 596 children (79%). The median dose associated with major effects was 50.0mg (Mean: 106.0) compared with 40.0mg (Mean 81.1) for moderate effects. Half (50.0%) of children with a major effect and 54.0% with a moderate effect ingested ≤40 mg of vilazodone. As the dose of vilazodone ingested increased, the proportions of exposures admitted to a healthcare facility (HCF) (p < .001) and with serious outcomes (p < .001) both increased. Children ≤2 years had higher proportions of HCF admission (33.8% vs 23.1%) and serious outcomes (27.0% vs 17.7%) than children 3-5 years of age. Clinical effects, such as coma, seizures, ataxia, and hallucinations/delusions, were observed among children ingesting doses of vilazodone as low as 10 mg.
CONCLUSIONS: Exposure to vilazodone poses a unique and potentially serious threat to children <6 years of age. Children in this age group who are exposed to vilazodone should be evaluated promptly in a clinical setting. Off-label use of vilazodone in children under 6 years should be discouraged until further research is conducted regarding its safety in this population.
参考来源
- Gaw CE, Spiller HA, Russell JL, et al. Evaluation of dose and outcomes for pediatric vilazodone ingestions. Clin Toxicol (Phila). 2017. PMID: 28705022. doi:10.1080/15563650.2017.1347263
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。